About 14 results found for searched term "PD-1/PD-L1" (0.057 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M5144 | BMS202 | PD-1/PD-L1 |
| PD-1/PD-L1 inhibitor 2 | ||
| Bms-202 is an effective non-peptide PD-1/PD-L complex inhibitor with IC50 of 18 nM and KD of 8 μM. Bms-202 directly binds to PD-L1 and blocks the human PD-1/PD-L interaction. Bms-202 has antitumor activity. | ||
| M8959 | BMS-1 (PD-1/PD-L1 inhibitor 1, PD1-PDL1-IN1) | PD-1/PD-L1 |
| BMS-1 (PD-1/PD-L1 inhibitor 1, PD1-PDL1-IN1) is an inhibitor of PD-1/PD-L1 protein/protein interaction with an IC50 of 6 to 100 nM. | ||
| M11354 | INCB086550 | PD-1/PD-L1 |
| PD-1/PD-L1-IN-8 | ||
| INCB086550 selectively inhibited PD-L1 with IC50 of 3.1 nM, 4.9 nM and 1.9 nM for human, rhesus monkey and rat pD-L1, respectively. INCB086550 could not inhibit the binding of PD-L2 to PD-1 at 10 μM. INCB086550 significantly inhibits the PD-1/PD-L1 signaling axis by binding to PD-L1 protein, leading to PD-L1 dimerization and internalization, and has good tumor suppressive effect in a variety of mouse tumor models. | ||
| M11456 | Evixapodlin | PD-1/PD-L1 |
| PD-1/PD-L1-IN 7; GS-4224 | ||
| Evixapodlin (PD-1/ PD-L1-in 7) is an inhibitor of human PD-1/PD-L1 protein/protein interaction with an IC50 of 0.213 nM. Evixapodlin has anti-cancer and anti-virus properties. | ||
| M24961 | PD-1/PD-L1-IN-20 | PD-1/PD-L1 |
| PD-1/PD-L1-IN-20 (Example 21) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-20 blocks PD-1/PD-L1 with the IC50 of 5.29 nM. PD-1/PD-L1-IN-20 can be used for the research of cancers, infectious diseases and autoimmune diseases. | ||
| M28729 | PD-1/PD-L1-IN 3 | PD-1/PD-L1 |
| PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases. | ||
| M29576 | PD-1/PD-L1-IN-NP19 | PD-1/PD-L1 |
| PD-1/PD-L1-IN-NP19 is a PD-1/PD-L1 inhibitor, with an IC50 of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenvironment in tumor, which may contribute to its antitumor effects. | ||
| M29649 | PROTAC PD-1/PD-L1 degrader-1 | PROTAC |
| PROTAC PD-1/PD-L1 degrader-1, a PD-1/PD-L1 PROTAC based on Cereblon E3 ligand, inhibits PD-1/PD-L1 interaction with an IC50 of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. PROTAC PD-1/PD-L1 degrader-1 moderately reduces the protein levels of PD-L1 in a lysosome-dependent manner. | ||
| M29673 | PD-1/PD-L1-IN-10 | PD-1/PD-L1 |
| PD-1/PD-L1-IN-10 (compound B2) is an orally active PD-1/PD-L1 inhibitor (IC50 of 2.7 nM) with potent anticancer efficacy. | ||
| M31044 | PD-1/PD-L1-IN 3 TFA | PD-1/PD-L1 |
| PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. | ||
| M31307 | MAX-10181 | PD-1/PD-L1 |
| PD-1/PD-L1-IN-30 | ||
| MAX-10181 (PD-1/PD-L1-IN-30) is a PD-1/PD-L1 binding inhibitor with an IC50 value of 0.018 μM.It can be used in studies related to solid tumors. | ||
| M42030 | PD-1/PD-L1-IN-32 | PD-1/PD-L1 |
| PD-1/PD-L1-IN-32 is a potent PD-1/PD-L1 inhibitor (IC50=2.4 nM), with anticancer activity. | ||
| M42033 | PD-1/PD-L1-IN-31 | PD-1/PD-L1 |
| PD-1/PD-L1-IN-31 is a PD-1/PD-L1 inhibitor (IC50=2.2 nM). | ||
| M42034 | PD-1/PD-L1-IN-33 | PD-1/PD-L1 |
| PD-1/PD-L1-IN-33 is a PD-1/PD-L1 inhibitor. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
